Universität zu Köln

Olschewski, Horst ORCID: 0000-0002-2834-7466, Behr, Juergen, Bremer, Hinrich, Claussen, Martin, Douschan, Philipp, Halank, Michael, Held, Matthias, Hoeper, Marius M., Holt, Stephan, Klose, Hans, Krueger, Stephan ORCID: 0000-0002-1658-5993, Lange, Tobias J., Reichenberger, Frank ORCID: 0000-0003-1136-4769, Skowasch, Dirk, Ulrich, Silvia ORCID: 0000-0002-5250-5022, Wilkens, Heinrike ORCID: 0000-0002-7789-8563 and Seeger, Werner ORCID: 0000-0003-1946-0894 (2018). Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018. Int. J. Cardiol., 272. S. 63 - 69. CLARE: ELSEVIER IRELAND LTD. ISSN 1874-1754

Full text not available from this repository.

Abstract

The 2015 European Guidelines on Pulmonary Hypertension did not only cover pulmonary arterial hypertension (PAH) but also some aspects of pulmonary hypertension (PH) associated with chronic lung disease. The European Guidelines point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, sGC stimulators) have not been sufficiently investigated in other forms of PH. Therefore, the European Guidelines do not recommend the use of these drugs in patientswith chronic lung disease and PH. This recommendation, however, is not always in agreement with medical ethics as physicians sometimes feel inclined to treat other forms of PHwhichmay affect quality of life and survival of these patients in a similar manner. To this end, it is crucial to consider the severity of both PH and the underlying lung disease. In June 2016, a Consensus Conference organized by the PHworking groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Paediatric Cardiology (DGPK) was held in Cologne, Germany, to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were created, one of which was dedicated to the diagnosis and treatment of PH in patients with chronic lung disease. The 2018 updated recommendations of this working group are summarized in the present paper. (c) 2018 Published by Elsevier B.V.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Olschewski, Horst UNSPECIFIED orcid.org/0000-0002-2834-7466 UNSPECIFIED Behr, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED Bremer, Hinrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Claussen, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Douschan, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Halank, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Held, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoeper, Marius M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Holt, Stephan UNSPECIFIED UNSPECIFIED UNSPECIFIED Klose, Hans UNSPECIFIED UNSPECIFIED UNSPECIFIED Krueger, Stephan UNSPECIFIED orcid.org/0000-0002-1658-5993 UNSPECIFIED Lange, Tobias J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reichenberger, Frank UNSPECIFIED orcid.org/0000-0003-1136-4769 UNSPECIFIED Skowasch, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED Ulrich, Silvia UNSPECIFIED orcid.org/0000-0002-5250-5022 UNSPECIFIED Wilkens, Heinrike UNSPECIFIED orcid.org/0000-0002-7789-8563 UNSPECIFIED Seeger, Werner UNSPECIFIED orcid.org/0000-0003-1946-0894 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-162596
DOI:	10.1016/j.ijcard.2018.08.043
Journal or Publication Title:	Int. J. Cardiol.
Volume:	272
Page Range:	S. 63 - 69
Date:	2018
Publisher:	ELSEVIER IRELAND LTD
Place of Publication:	CLARE
ISSN:	1874-1754
Language:	English
Faculty:	Faculty of Mathematics and Natural Sciences
Divisions:	Faculty of Mathematics and Natural Sciences > Department of Biology > Botanical Institute
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DIFFUSION CAPACITY; CLINICAL CHARACTERISTICS; EMPHYSEMA SYNDROME; PROGNOSTIC-FACTORS; CONTROLLED-TRIAL; FIBROSIS; COPD; SILDENAFIL; PRESSURE; SURVIVAL Multiple languages Cardiac & Cardiovascular Systems Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/16259